CMP Pharma and Kiel Laboratories Sign Development Agreement
News Mar 07, 2014
CMP Pharma and Kiel Laboratories have signed an agreement to develop, seek regulatory approval, and commercialize two new prescription drugs.
The first drugs will be directed at the general population with special emphasis on the geriatric market, followed by a product to be directed at the pediatric market.
While both drugs already exist as FDA approved solid dosage forms, CMP will be filing NDAs to obtain approval for an alternate liquid dosage form.
Commenting on the agreement, Gerald Sakowski, CEO of CMP Pharma, said, “These two products are excellent complements to our line of niche specialty pharmaceutical products. This is another chapter in our long history of developing stable, ready-to-use liquid dosage forms that make life easier on the consumer, the physician, and the pharmacist.”
Electron Microscope Detector Achieves Record ResolutionNews
Like driving at night and being able to read the license plate of an oncoming car without being blinded by the lights.READ MORE
Chemistry Professor Awarded Prestigious Steenbock ProfessorshipNews
University of Wisconsin–Madison Professor of Chemistry Shannon Stahl has received the Steenbock Professorship in Chemical Sciences. In addition to advancing the fundamental science in this area, Stahl has been involved in numerous industrial collaborations that have led to practical applications, including target applications relevant to pharmaceutical synthesis.READ MORE
Enabling Technology in Cell-Based Therapies: Scale-Up, Scale-Out or Program In-PlaceNews
Technologies are reducing costs and changing the ways in which researchers and clinicians process and use therapeutic cells. Two new review articles detail the status of cell bioreactors in both stem cell and tissue/organ engineering applications.READ MORE
15th International Conference and Exhibition on Metabolomics & Systems
Apr 29 - Apr 30, 2019